Navigation Links
New England Peptide Names Director of Chemical Development
Date:9/30/2008

New England Peptide, LLC (NEP), has named Robert P. Hammer, Ph.D., director of chemical development.

Gardner, Mass. (PRWEB) September 30, 2008 -- New England Peptide, LLC (NEP), has named Robert P. Hammer, Ph.D., director of chemical development.

Hammer comes to NEP from Louisiana State University (LSU), where he was the William A. Pryor professor of chemistry since 2006. Prior to 2006, he held assistant professor, associate professor, and professor positions in chemistry at the university. Before his work at LSU, Hammer completed a post-doctoral fellowship at the Swiss Federal Institute of Technology (ETH) in Zurich.

During his tenure at LSU, Hammer served as principal investigator on a number of grants from organizations including the National Science Foundation and the National Institutes of Health (NIH). He also received an NIH senior research fellowship at Purdue University, during sabbatical from LSU.

The new director is the recipient of a dozen major national and international honors and awards, including the LSU Distinguished Faculty Award; LSU College of Basic Sciences Outstanding Teacher Award; and the Lee Irvin Smith Award for High Ability and Leadership in Organic Chemistry (University of Minnesota).

Hammer is the author of nearly 100 scientific papers, including 59 research articles in refereed journals. He also has participated in the preparation of more than 60 abstracts and meeting contributions, is a frequent lecturer and holds 12 patents. His research has focused on the design, synthesis, and biophysical and biological evaluation of peptide and nucleic acid analogs, and the development of near-infrared dyes for bioconjugation. In 2006, his work on peptide analogues for inhibiting amyloid protein aggregation was recognized as part of the Scientific American 50.

A member of Phi Beta Kappa, Hammer holds a Bachelor of Science degree in chemistry, with distinction, from the University of Illinois, and a doctoral degree in organic chemistry from the University of Minnesota, where he worked with research advisor George Barany, Ph.D. Barany studied under Bruce Merrifield, the American biochemist who won the Nobel Prize in chemistry in 1984 for the invention of solid phase peptide synthesis.

"Bob brings tremendous experience and perspective in complex peptide synthesis to NEP," says Dave Robinson, NEP's CEO. "His background and research expertise perfectly complement NEP's focus on delivering discovery and preclinical services, and preparation to move into the clinical and commercial-grade peptide markets. His style and thought leadership fit well with NEP's emphasis on quality, service and culture of continuous improvement."

New England Peptide (www.newenglandpeptide.com [www.newenglandpeptide.com __title__ New England Peptide Web site]), founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company's chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.

Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, obesity and HIV/AIDS. Peptides' inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in research and clinical use. All segments of the peptide market - from therapeutics and vaccines to diagnostics and cosmetics - are thriving.

# # #

Read the full story at http://www.prweb.com/releases/peptides/research/prweb1388964.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. New England Peptide Implements Quality Management System, Prepares for ISO 9001: 2008 Registration
2. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
3. NeoStem Announces Private Placement Financing to Advance Marketing Campaign; Financing Includes Investment from New England Cryogenic Center
4. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
5. Tandem Labs New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology.
8. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
9. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
10. ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
11. Codexis Names Vice President, Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New England Peptide Names Director of Chemical Development
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/9/2016)... in attendance control systems is proud to announce the introduction of fingerprint attendance control ... right employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
Breaking Biology News(10 mins):